ArticleSurgery2013
An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
Article in Surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- A Glimpse in the Future of Malignant Mesothelioma Treatment.Frontiers in pharmacology · 2021Review
- High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma.Molecular therapy oncolytics · 2020Article
- Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.Translational lung cancer research · 2020Review
- Isolation and Complete Genome of the Marine Pseudoalteromonas Phage C7 from Coastal Seawater of Yellow Sea, China.Current microbiology · 2020Article
- Progress in the Management of Malignant Pleural Mesothelioma in 2017.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Review
- Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.Journal of thoracic disease · 2018Article
- Characterization and Complete Genome Sequence of a Novel Siphoviridae Bacteriophage BS5.Current microbiology · 2017Article
- Immunotherapy for malignant pleural mesothelioma: current status and future directions.Translational lung cancer research · 2017Review
- Novel immunotherapy clinical trials in malignant pleural mesothelioma.Annals of translational medicine · 2017Article
- The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.Annual review of physiology · 2017Review
- Viroimmunotherapy of Thoracic Cancers.Biomedicines · 2017Review
- Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.Frontiers in oncology · 2017Review
- Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.Oncolytic virotherapy · 2017Review
- Oncolytic Viral Therapy for Mesothelioma.Frontiers in oncology · 2017Review
- Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.Gene therapy · 2016Article
- The use of the NIS reporter gene for optimizing oncolytic virotherapy.Expert opinion on biological therapy · 2016Review
- Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma.Cancer gene therapy · 2015Article
- Article
- Oncolytic virotherapy for human malignant mesothelioma: recent advances.Oncolytic virotherapy · 2015Review
- Molecular imaging of oncolytic viral therapy.Molecular therapy oncolytics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe purpose of this work was to examine the ability of an oncolytic vaccinia virus expressing the human sodium iodine transporter (hNIS) to provide real time monitoring of viral therapy and effective treatment of malignant pleural mesothelioma (MPM).
methodsInfectivity and cytotoxic effects of GLV-1h153 on mesothelioma cell lines of all histologic subtypes were assayed in vitro. Viral replication was examined by standard viral plaque assay. Orthotopic MPM xenografts were generated in athymic nude mice, treated with intrapleural GLV-1h153, and assessed for effect on tumor burden and survival. Orthotopic tumors were also imaged on single photon emission computed tomography (SPECT)/computed tomography (CT) after (131)I administration.
resultsGLV-1h153-infected and killed all cell lines in a time- and concentration-dependent manner. Viral replication demonstrated a >2.5-log increase in titer over 4 days. Intrapleural treatment of orthotopic MPM xenografts resulted in a significant decrease in tumor burden 1 week after treatment and an improvement in survival. Infection of orthotopic xenografts was both therapeutic and facilitated monitoring by (131)I-SPECT/CT via expression of hNIS in infected tissue.
conclusionOur results suggest that GLV-1h153 may be a promising therapeutic agent for MPM and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.